FAIRFIELD, Conn., Nov. 1 /PRNewswire-FirstCall/ -- Competitive
Technologies, Inc. (Amex: CTT) announced today that patent number 6,808,561
has been issued by the US Patent Office for Dr. Brian R. Genge's
nanotechnology bone biomaterial developed at the University of South Carolina
(USC). CTT has an exclusive agreement with the University of South Carolina
Research Foundation to license and commercialize the nanotechnology, an
injectible calcium phosphate-based biomaterial. Dr. Genge is a research
professor in the Department of Chemistry and Biochemistry at USC.
"The granting of this patent recognizes the unique qualities of Dr.
Genge's innovative nanoparticle biomaterial technology," said Suzanne N. B.
Alent, CTT's VP Marketing and Business Development. "CTT has an agreement with
a major dental products company to research the manufacture and use of this
nanotechnology for dental applications. We will continue to aggressively
market this superior technology for all aspects of its capabilities."
In addition to its use in the dental field, the patented nanotechnology
can also be applied to a variety of human orthopedic procedures, especially
related to the spine and craniofacial reconstruction, as well as veterinary
uses. The bone biomaterial technology is an easily flowable, moldable paste
that conforms to and interdigitates with the host bone. It rapidly hardens
itself in vivo, forming a solid bone-like structure capable of stabilizing
fractured bone within 15 minutes and supports the growth of cartilage and bone
cells. The technology has superior compressive strength making it suitable for
weight and non-weight bearing bones, and is both machinable and drillable.
John B. Nano, CTT's President and CEO said, "CTT is proud to continue its
successful relationship with USC and Dr. Genge. We are building and renewing
our strong, global alliances with universities, companies and individual
inventors. Bone biomaterial is just one of the exciting technologies in CTT's
innovative portfolio. We are actively marketing and commercializing several
technologies, including homocysteine assays, video compression and decoding
technology, sexual dysfunction treatment, sunless tanning application, silicon
carbide wafer testing, encryption technology, EZSpeech(TM) language-mastering
software, an anti-cancer compound and the Therapik(R) device."
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, is a full service
technology transfer and licensing provider focused on the technology needs of
its customers and transforming those requirements into commercially viable
solutions. CTT is a global leader in identifying, developing and
commercializing innovative technologies in life, digital, nano, and physical
sciences developed by universities, companies and inventors. The global market
for technology transfer services is estimated at $150 billion annually. CTT
maximizes the value of intellectual assets for the benefit of its customers,
clients and shareholders. Visit CTT's website: http://www.competitivetech.net
Statements about our future expectations, including development and
regulatory plans, and all other statements in this document other than
historical facts are "forward-looking statements" within the meaning of
applicable Federal Securities Laws, and are not guarantees of future
performance. These statements involve risks and uncertainties inherent in our
business, including those set forth in Item 7 under the caption "Risk
Factors," in our most recent Annual Report on Form 10-K filed with the SEC on
October 29, 2004, and other factors that may be described in our other filings
with the SEC, and are subject to change at any time. Our actual results could
differ materially from these forward-looking statements. We undertake no
obligation to update publicly any forward-looking statement.
Direct inquiries to: Johnnie D. Johnson, Strategic IR, Inc.
Tel. (212) 754-6565; Fax (212) 754-4333
SOURCE Competitive Technologies, Inc.